Spironolactone Use in End-Stage Chronic Kidney Disease

Introduction to Spironolactone Risks

Spironolactone should be avoided in patients with end-stage chronic kidney disease (eGFR <30 mL/min/1.73m²) due to the significantly increased risk of hyperkalemia and potential for cardiac arrest 1

The American College of Cardiology/American Heart Association guidelines explicitly state that spironolactone should be avoided when serum creatinine is greater than 2.5 mg/dL in men or greater than 2.0 mg/dL in women (or eGFR <30 mL/min/1.73 m²) 3
Inappropriate use of aldosterone receptor antagonists is potentially harmful because of life-threatening hyperkalemia or renal insufficiency in patients with advanced kidney disease 3
For patients with heart failure, the guidelines specify that creatinine should be ≤2.5 mg/dL in men or ≤2.0 mg/dL in women (or eGFR >30 mL/min/1.73 m²), and potassium should be <5.0 mEq/L before initiating spironolactone 3

The risk of hyperkalemia with spironolactone increases progressively as renal function declines 1
Risk factors that further increase hyperkalemia risk include concomitant use of ACE inhibitors or ARBs 1, 2
Baseline potassium ≥5.0 mEq/L is also a risk factor for hyperkalemia 1
Diabetes mellitus increases the risk of hyperkalemia 1
Use of NSAIDs or COX-2 inhibitors increases the risk of hyperkalemia 1
Concurrent use of other potassium-sparing diuretics increases the risk of hyperkalemia 1

For patients with heart failure and end-stage CKD, alternative pharmacological treatments should be considered 4
A combination of nitrates and hydralazine has shown favorable effects on survival in patients with mild to moderate heart failure symptoms 4
For blood pressure control in CKD patients, other antihypertensive medications with better safety profiles in advanced kidney disease should be considered 5

If spironolactone must be used in a patient with advanced CKD, start with very low doses (12.5 mg daily or every other day) and monitor potassium and renal function at 3 days and 1 week after initiation, and at least monthly thereafter 1
Discontinue spironolactone immediately if potassium ≥6.0 mEq/L 1
Consider hospitalization for initiation to allow for close monitoring 3